2025 Reseach Roundup

A series of 2024–2025 studies and a veterans' roundtable underscore regulatory, public-health and product-quality issues in the cannabis sector: on Jan 17, 2025 the Veterans Action Council hosted Dr. Ethan Russo to discuss cannabinoid hyperemesis syndrome (Russo co‑authored an Oct 2024 Frontiers in Toxicology paper on genetic susceptibility), a Jan 2025 Journal of Studies on Alcohol and Drugs paper (funded by the California Department of Cannabis Control) surveyed perspectives on mandatory dispensary warning signs required in Arizona, Colorado, Illinois, Oregon and Washington, and a Johns Hopkins clinical trial in 19 adults found oral synthetic delta‑8 THC produced dose‑dependent psychoactive effects similar but milder than delta‑9 (delta‑8: 10/20/40 mg; delta‑9: 20 mg). Additional research flagged commercial risks: University of Kentucky testing of 56 CBG gummy products via LC‑MS‑MS revealed inconsistent cannabinoid labeling, while MoreBetter Ltd reported that low‑dose hemp beverages are associated with reduced alcohol use and urged lawmakers to consider these findings ahead of FY2026 Agriculture–FDA appropriations language. Collectively the reports point to persistent product-quality issues and regulatory scrutiny that investors should weigh when assessing cannabis and hemp exposures.

Analysis

Market structure: Winners include regulated MSOs and large beverage/CPG incumbents that can pivot to compliant low‑THC/hemp beverages (Tilray TLRY, Canopy CGC, Curaleaf CURLF) and third‑party testing labs that capture margin from mandatory testing; losers are small direct‑to‑consumer CBD/CBG brands with poor labeling and delta‑8/grey‑market operators facing enforcement. Expect pricing power to concentrate with players that secure supply chains and compliance — 10–30% margin advantage versus mom‑and‑pop brands within 12–24 months. Cross‑asset: hemp regulation headlines will move CAD‑listed cannabis equities, widen equity vols, and modestly pressure alcohol beverage stocks if substitution trends persist (see STZ exposure).

Risk assessment: Tail risks include a federal clampdown on delta‑8 or omnibus language effectively banning certain hemp beverages (low probability but high impact, 10–20% downside to small‑cap hemp names within 30–90 days). Immediate horizon (days–weeks): headline volatility around FY2026 Agriculture–FDA appropriations timing (omnibus vote expected within next 30–60 days). Short‑term (weeks–months): litigation from mislabeling and state MWS policy shifts; long‑term (1–3 years): consolidation and FDA regulatory clarity that favors vertically integrated, compliant firms. Hidden dependency: many small players lack capital to relabel/retest — forcing M&A or exits that concentrate supply.

Trade implications: Tactical long exposure to large, balance‑sheet‑healthy MSOs (TLRY, CGC) sized 1–3% each, hedge via 0.5–1% short in large alcohol name STZ or consumer staples ETF (XLP) to capture substitution risk; target 6–12 month horizon, stops at 30% adverse move, upside targets +50–100% if regulatory tailwinds materialize. Use options to define risk: buy 3‑month TLRY 25–40% OTM call spreads (cost <3% position) ahead of omnibus/FDA clarity; buy 2–3% portfolio protection via OTM puts on small‑cap CBD indices or CURLF for regulatory tail risk. Rotate out of pure CBD/CBG single‑product small caps into testing/lab services and compliant MSOs as labeling rules tighten.

Contrarian angles: Market may underprice upside from harm‑reduction narrative (delta‑8 milder effects + low‑dose hemp beverages) that can expand addressable market 10–25% vs. current forecasts if FDA tolerates low‑dose products; conversely, reaction could be overdone for small caps assuming immediate nationwide bans — history (EVALI 2019) shows regulatory shock can temporarily crush small players but accelerates consolidation that benefits larger firms. Watch for unintended consequence: stricter labeling/testing increases time‑to‑market and raises switching costs, advantaging well‑capitalized MSOs and lab providers over nimble but undercapitalized startups.

Key Decisions for Investors

• Establish a 2% long position in TLRY and a 1.5% long in CGC over the next 30 days as a leveraged bet on regulated hemp beverage uptake and consolidation; set stop‑loss at -30% and a 12‑month upside target of +50–100% conditional on favorable omnibus language or FDA non‑action.
• Initiate a 1% short position in STZ (or equivalent 0.5–1% short via XLP) to hedge alcohol substitution risk from low‑THC/hemp beverages; cover if STZ underperforms consumer staples by >5% over any 60‑day period or if omnibus language clearly protects hemp beverages.
• Buy a 3‑month TLRY 25–40% OTM call spread (risk limited to premium <0.5–1% of portfolio) to play a regulatory or product‑launch upside around the expected FY2026 appropriations window (30–60 days); exit on passage/no‑action or if IV rises >40%.
• Reduce or avoid direct exposure (>1% position) to small‑cap pure‑play CBD/CBG brands lacking third‑party testing; reallocate 1–3% into publicly traded testing labs or MSOs with in‑house labs once labeling regulations are formalized (trigger: publication of FDA/agriculture language or state MWS enforcement actions within 60 days).
• Purchase 6–9 month out‑of‑the‑money puts (cheap protection equal to 0.5–1% of portfolio) on small‑cap cannabis/CBD ETFs or OTC tickers (e.g., CURLF tail hedge) to guard against a regulatory clampdown scenario; deploy if omnibus language includes restrictive hemp definitions or delta‑8 bans.